Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554291 · ClinicalTrials.gov registry record · Phase 2
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03554291 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 80 participants.
The verdict
NCT03554291, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.
Interventions
- OTHER Placebo
- DRUG Famotidine 20 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03554291
The ClinicalTrials.gov registry entry for NCT03554291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03554291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03554291 about?
NCT03554291 is a clinical study titled "Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension". This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.
What is the current status of trial NCT03554291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2019-05-01. Estimated completion is 2023-07-11.
What interventions are being tested in trial NCT03554291?
The interventions under investigation include: Placebo (OTHER), Famotidine 20 MG (DRUG).
Who is sponsoring clinical trial NCT03554291?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.